Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Interlace Medical raises $20.5mm through its Series C round

Executive Summary

Interlace Medical (gynecological devices) has raised $20.5mm through its Series C venture round. Baird Venture Partners and HLM Venture Partners led the financing and were joined by fellow new investors H&Q Capital Management and Aperture Venture Partners, and current backers New Leaf Venture Partners and Spray Venture Partners. Representatives from Baird and HLM will take seats on the company's board. Interlace will use the proceeds to market its MyoSure minimally invasive device for uterine fibroids and polyps.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies